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ABSTRACT
Objective: The aim of this study is to review highly
cited articles that focus on non-publication of studies,
and to develop a consistent and comprehensive
approach to defining (non-) dissemination of research
findings.
Setting: We performed a scoping review of definitions
of the term ‘publication bias’ in highly cited
publications.
Participants: Ideas and experiences of a core group
of authors were collected in a draft document, which
was complemented by the findings from our literature
search.
Interventions: The draft document including findings
from the literature search was circulated to an
international group of experts and revised until no
additional ideas emerged and consensus was reached.
Primary outcomes: We propose a new approach to
the comprehensive conceptualisation of (non-)
dissemination of research.
Secondary outcomes: Our ‘What, Who and Why?’
approach includes issues that need to be considered
when disseminating research findings (What?), the
different players who should assume responsibility
during the various stages of conducting a clinical trial
and disseminating clinical trial documents (Who?), and
motivations that might lead the various players to
disseminate findings selectively, thereby introducing
bias in the dissemination process (Why?).
Conclusions: Our comprehensive framework of (non-)
dissemination of research findings, based on the results
of a scoping literature search and expert consensus will
facilitate the development of future policies and
guidelines regarding the multifaceted issue of selective
publication, historically referred to as ‘publication bias’.
BACKGROUND
Systematic reviews of randomised controlled
trials provide a valid summary of the
available research ﬁndings, and are therefore
crucial to evidence-based medical decision-
making.1 It has long been recognised that
identiﬁcation of the entire relevant research
evidence is essential to produce an unbiased
and balanced summary, although non-
dissemination of research ﬁndings may not
necessarily lead to bias. For example, a
journal publication may report on all prespe-
ciﬁed outcomes and time points, but raw
data may still be important for other
researchers and research questions. This dis-
semination is not biased or selective, but,
rather, a result of the current publication
system. Nevertheless, ideally, all research con-
ducted should be published and easily identi-
ﬁable. Only under such circumstances can
systematic reviews live up to their promise of
providing unbiased, high-quality evidence for
medical decision-making. However, it is not
Strengths and limitations of this study
▪ We present a new comprehensive framework
based on results from literature review and inter-
national expert consensus on (non-) dissemin-
ation of research results.
▪ Our three step approach considers, for the first
time, issues that need to be taken into account
when disseminating research findings (What?),
different players who should assume responsibil-
ity (Who?) and motivations that might lead to
selective dissemination of research findings
(Why?).
▪ We only searched Web of Science, with the
simple search term ‘publication bias’. This way,
our literature search might have favoured older
publications and systematic reviews of primary
research.
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always possible to retrieve all eligible evidence for a
given topic, as many studies never get published. The
phenomenon of non-publication of studies based on the
nature and direction of the results is often referred to as
‘publication bias’.2 3
Interpretations of research evidence can be distorted
not only by the non-publication of an entire study—
information may also be partially lacking or presented in
a way that inﬂuences the take-up of the ﬁndings, such as
selective reporting of outcomes or subgroups, or ‘data
massaging’ (eg, the selective exclusion of patients from
the analysis). Thus, over recent years, a new nomencla-
ture for other types of bias related to the non-
publication or distortion in the dissemination process of
research ﬁndings has been developed, such as ‘reporting
bias’,4 ‘time lag bias’,5 ‘location bias’,6 7 and many more.
Nevertheless, all these different aspects are often still
referred to as ‘publication bias’. Until now, no consensus
on the deﬁnition of ‘publication bias’ has been reached
in the literature.
Therefore, we aimed to perform a scoping review of
highly cited articles that focus on non-publication of
studies and to present the various deﬁnitions of biases
related to the dissemination of research ﬁndings con-
tained in the articles identiﬁed. Furthermore, we aimed
to develop a comprehensive and consistent framework
to deﬁning (non-) dissemination of research ﬁndings in
an international group of experts in the context of the
OPEN Project (To Overcome failure to Publish nEgative
ﬁNdings) based on the ﬁndings of our literature search.
METHODS
A detailed protocol of our methods has been pub-
lished.8 In brief, the following methods were used for lit-
erature search and the development of the ‘what, who
and why?’ framework to deﬁning (non-) dissemination
of research ﬁndings.
Literature search
Search strategy
Our focus was on highly cited and publicly available arti-
cles in order to capture the most widely used deﬁnitions
of ‘publication bias’. Therefore, we searched Web of
Science9 on 19 November 2012. We used the simple
search term ‘publication bias’, which had to be included
in the title or abstract and also in the keywords. We
chose Web of Science because it presents results of lit-
erature searches according to the total number of cita-
tions, therefore allowing us to identify the most
frequently cited articles. Although we were interested in
various aspects of problems in the dissemination process
of research ﬁndings, we aimed at the identiﬁcation of
different deﬁnitions of ‘publication bias’ and thus
decided that the term ‘publication bias’ should be part
of all publications of interest. No language restrictions
were applied. We did not search any other database or
any grey literature.
Eligibility criteria
We included the 50 most frequently cited articles that
focused on biases related to the non-publication or dis-
tortion in the dissemination process of research ﬁndings
from any source and addressed to any audience. Since
we were interested in the most common deﬁnitions of
‘publication bias’, we believed that 50 articles would
provide enough information. We did not exclude self-
citations, because we were interested in the absolute
number of citations independent of the people who
cited the work. In order to be included, articles needed
to use the term ‘publication bias’ and provide some form
of deﬁnition of it. We included only full-text articles.
Study selection
Two reviewers independently screened titles and
abstracts of search results. If a title or abstract could not
be rejected with certainty by both reviewers, the full text
of the paper was retrieved and assessed for eligibility.
Any disagreement among reviewers was resolved by dis-
cussion and consensus or, if needed, by third party
arbitration.
Data extraction
A specially designed data extraction form was developed
and pilot-tested. KFM and DB independently extracted
all relevant information from each eligible article. The
following information was collected:
▸ General characteristics (eg, author names, language
and year of publication, journal)
▸ Number of citations in Web of Science and rank
▸ Deﬁnitions of biases related to the dissemination of
research ﬁndings
Any disagreement was resolved by discussion and con-
sensus or, if needed, arbitration by a third reviewer.
Data analysis and reporting
Data synthesis involved a descriptive summary of the
range of deﬁnitions given to describe various forms of
biases related to the dissemination of research ﬁndings.
Development of the OPEN framework of (non-)
dissemination of research findings
We performed a scoping review of deﬁnitions of the
term ‘publication bias’ in highly cited publications. In a
second step, we proposed a draft regarding the issues
that need to be considered when exploring possible
biases due to selective dissemination of research ﬁndings
capturing the ideas and experiences of the core group
of authors. We then circulated the draft to all the
co-authors and, in a third step, to all members of the
OPEN consortium (an international group of experts).
Experts reviewed the draft and provided feedback, as
required, regarding the issues we identiﬁed, or contribu-
ted other insights. We continued this process until no
additional ideas emerged. There have been three
rounds of feedback: In the ﬁrst round, 8 of 10 authors
commented, in the second round, 5 of 10 authors
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commented and, in the last round, 9 of 10 authors
commented.
At the end of this process, we reached consensus
regarding the issues that need to be considered when
exploring possible biases due to selective dissemination
of research ﬁndings. Based on this consensus, targeted
measures to reduce dissemination bias can be developed
and implemented.
RESULTS
Review of existing definitions of ‘publication bias’
We included the 50 most highly cited articles that pro-
vided a deﬁnition of ‘publication bias’ (see online sup-
plementary ﬁle 1: included articles). Further information
about the included articles is given in online supplemen-
tary ﬁle 2: General characteristics of included articles.
Most of the articles (38/50 articles) deﬁned ‘publica-
tion bias’ as a form of selective publication, for various
reasons (ﬁgure 1).
Five of the 50 included articles argued that ‘publication
bias’ as a term is not appropriate and that the authors
prefer to call this phenomenon ‘submitting/editing bias’.
OPEN framework of (non-) dissemination of research
findings
We suggest that the traditionally used term ‘publication
bias’ is too limited as it does not include all the
various problems that can occur in the process of dis-
seminating research ﬁndings. We therefore propose to
use the term ‘dissemination bias’ rather than ‘publica-
tion bias’, as suggested by others,10 11 because it cap-
tures various other problems that can occur
throughout the entire process, from the planning and
conduct of studies to the dissemination of research
evidence.
More importantly, we propose a comprehensive and
consistent approach to the issue of (non-) dissemination
of research ﬁndings that, in part, focuses on the various
key groups involved in the knowledge generation and
dissemination process. The proposed approach includes
three parts: (1) issues that need to be considered when
exploring possible biases due to selective dissemination
of research ﬁndings (What?), (2) stakeholders who
could assume responsibility for the various stages of con-
ducting a clinical trial and disseminating clinical trial
documents (Who?) and (3) motivations that may lead
the various players to disseminate ﬁndings selectively,
thereby introducing bias in the dissemination process
(Why?).
Issues that need to be considered when exploring possible
biases due to selective dissemination of research findings
(What?)
Based on our scoping review and our experience, the
existing deﬁnitions of ‘publication bias’ remain rather
vague, as there is currently no agreement in the scientiﬁc
community about what should be considered a ‘publica-
tion’ and how it should be deﬁned. It is unclear if only a
full article in a peer-reviewed journal should be consid-
ered a publication, or whether other formats of
Figure 1 Various reasons for selective publication.
Table 1 Characteristics that need to be considered when disseminating research findings (What?)
Type of data Format/product Accessibility
▸ Individual data
– complete*
– incomplete†
▸ Summary
(analysed) data
– complete*
– incomplete†
▸ Grey literature (press, newspaper, any kind of report, patent, technical
report from government agencies or scientific research groups, working
paper from research groups or committees, executive summary, book
chapter, presentation at scientific conferences (abstracts, slides, posters),
dissertation/ thesis, trial register entry, submission to regulatory
authorities, database/statistical file*‡, regulatory drug trial reports)
▸ Full article published in a journal
▸ Regulatory documents (CSR (clinical study report), ISS (integrated
summary of effectiveness or safety), PSURS (periodic safety updates),
DAP (drug approval packages), EPAR (European public assessment
report), CTD (common technical documents))
▸ Study protocol, statistical analysis plan
▸ Case report forms
▸ Internal communication
▸ Open to all
▸ Available on request
▸ Restricted§
▸ Not available outside
primary research group
*All raw data.
†Selection of outcome data.
‡Analysed outcome data.
§Including paywall restrictions.
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Table 2 Responsibility/influence that different players could assume in the various steps of conducting a clinical trial and in the dissemination of clinical trial documents
(Who?)
Players in the dissemination process
Steps in trial
conduct and
dissemination
Researchers
authors
Journal
editors
Peer
reviewers
of journal
articles
Funding
agencies
Pharmaceutical
and medical
device
manufacturers
Research
ethics
committees
Research
institutions
Regulatory
agencies
Trial
register
Decision
making
bodies*
Readers/
patients/
patient
organisations/
benefit
assessment
agencies/HTA
bodies
Research idea/
research question
x x x x x
Writing the study
protocol
x x x x x
Registering the study
in a trial register
x x x x x x x x x
Submitting the study
protocol for a journal
publication
x x x x x x x x
Publishing the study
protocol
x x x x x
Conducting the study/
assessing outcome
measures
x x
Analysing data x x x
Writing and
submitting a journal
article
x x
Peer review x x
Publishing journal
research
x x x x x x
*Decision-making authorities in healthcare systems (eg, legal entities, such as the Federal Joint Committee in Germany).
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Table 3 Motivations of players that might lead to biased dissemination of research result (Why?)
Players Motivations
Researchers/authors Publish or perish
▸ The importance of scientists’ work is often judged by the amount of papers they publish. Journal
publications not only improve the visibility and reputation of investigators, but also represent an
increasingly important prerequisite for faculty positions and research funding.15 Therefore,
researchers might be pushed to preferably submit manuscripts with positive results, as they are
more likely to be published
Career status of authors
▸ Junior researchers may be less experienced and therefore may fear consequences less if
biased analyses are detected. They might also be in a hurry to generate the most publications
possible
▸ Junior and especially mid-career researchers are in need of frequent publications to progress
their academic careers, as survival in the system of science depends on reaching a critical
amount of publications within a certain time16
▸ Senior researchers have to make less effort to maintain their already well-established careers.
On the other hand, they might be in charge of an institution and therefore try to enhance its
publication record
Winner takes all
▸ Novel research findings are especially rewarded.16 Thus, authors will rush such results to a
journal. In order to be the first to publish with a minimum expenditure of resources, they will try
to anticipate which results are likely to be most impressive to reviewers and editors. On the other
hand, authors have no interest in ‘wasting their time’ in preparing manuscripts with results they
consider not sufficiently interesting to achieve publication.
Tendency to confirm own expectations and hypotheses
▸ Confirmations of one’s own expectations with significant results might be used as proof by
researchers that the procedure and findings are sound. Furthermore, a non-significant finding
may be interpreted as failure and therefore less ‘valuable’ or less ‘publishable’, as various
surveys and experiments have described15
Intellectual interest
▸ Apart from the tendency to confirm their own expectations and hypotheses, researchers wish to
demonstrate the truth of their own hypothesis to keep this research area open and not limit the
chance for further findings
Financial interests
▸ Researchers/authors might be pushed by funders/industry/lobby to report/submit research
findings in favour of the product and not submit unfavourable data.17 Furthermore, conflicts of
interest related to companies producing competing products may influence interpretation and
reporting of data by researchers/authors
Professional interests
▸ Researchers might be pushed to preferably publish results that support the current practice in
their respective medical specialty as conflicting results might be damaging to the reputation and
financial interest of their profession
Miscellaneous
▸ Researchers might decide not to share their data, as they want to benefit from the data
themselves, or do not want data to be scrutinised by others, or do not have time or resources to
make data available
Journal editors Frequent citations
▸ Editors are interested in publishing articles that accrue many citations, since frequent citations
increase the journal’s prestige and attract more readers, authors and subscribers.18 It is known
that ‘significant’ and theory-confirming results are more often cited by other authors
Reader interest
▸ Editors will try to anticipate the interest of readers (who will probably be more interested in new
and impressive results).
Tendency to confirm own expectations and hypotheses19
▸ Confirmations of editor’s expectations and significant results might be used as proof by editors
that the procedure and findings are sound
Financial interests20
▸ Journals receive financial rewards for publishing (eg, reprint sales or advertising revenue)
Conflict of interests
▸ Personal conflicts of interest might influence editors’ decision about manuscripts
Continued
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publication, such as presentations at scientiﬁc confer-
ences, governmental/institutional reports, book chap-
ters, dissertations and theses, should also be considered
as such. We decided to summarise the various ways of
making research results available to the public by the
term ‘dissemination’. The characteristics that need to be
considered when disseminating research ﬁndings are pre-
sented in table 1.
Stakeholders who should assume responsibility for the
various stages of conducting a clinical trial and
disseminating clinical trial documents (Who?), and their
motivations (Why?)
Within the OPEN Project, we have identiﬁed key groups
who are part of the knowledge generation and dissemin-
ation process.12 When exploring their policies and pro-
cedures to deal with publication and associated forms of
Table 3 Continued
Players Motivations
Peer reviewers Tendency to confirm own expectations and hypotheses19
▸ Confirmations of peer reviewer’s expectations and significant results might be used as proof by
peer reviewers that the procedure and findings are sound
Maximising reputation while minimising effort
▸ Peer reviewers have a very labour-intensive task18 and they inevitably have less insight into the
research done than the original authors. To minimise their workload they might solve the
information problem by relying on proxies to indicate the quality of research work. For example,
the status and reputation of authors, the strength and significance of results of the main results
as opposed to the scientific merit of the investigation, or even the tendency to confirm the peer
reviewer’s own expectations and hypotheses might serve as proxies
▸ Consequently, at times, well-designed and conducted studies may not be published if they
report null or negative results21
Conflict of interests
▸ Personal conflicts of interest might influence peer reviewers’ decision about manuscripts
(pharmaceutical and
device) manufacturers
Marketing of their product
▸ Commercial sponsors are interested in results supporting their product, and try to use such
results in the most favourable way for the marketing of their product. Likewise, they may wish to
suppress studies when the results do not favour their product
▸ It has been shown that industry-supported research is more likely to present ‘positive’ results
than research funded from non-industry sources, furthermore, industry sponsorship was strongly
associated with pro-industry conclusions.22–24 There is evidence that commercially sponsored
research is less frequently published if the results are ‘negative’22 24
Funding agencies Increase in visibility
▸ Funding agencies want to be visible and associated with promising research
Conflict of interests
▸ Funding agencies, in particular public funders such as hospitals, might be influenced by
economic considerations, and therefore favour less expensive treatment options over new and
more costly alternatives
Research ethics
committees
Lack of financial and personal resources
▸ While many research ethics committees sporadically check publications of approved studies,
they lack the financial and personal resources to do so in a systematic manner
Insufficient legal basis to require trial registration and unbiased dissemination
▸ While many research ethics committees would prefer to require trial registration and unbiased
dissemination of trial findings, most countries currently lack the legal basis for them to do so
Research institutions Increase in visibility
▸ Research institutions want to be visible and associated with promising research
Conflict of interests
▸ Conflicts of interest related to the performance of their own institution
Regulatory agencies Lack of realising the public interest in unbiased research
▸ While regulatory agencies need to protect commercial interests, their transparency policies
explicitly state that the public interest in unbiased clinical data can overrule the commercial
interests (especially after marketing approval has been granted). Nevertheless, recent decision
making of the European Medicines Agency on more or less restricted access to trial data did not
consider ‘public interest’ arguments25
Decision making
bodies*
Have an interest in transparency and try to add to the dissemination process through their
submission and publishing procedures
Readers/patients/patient
organisations
Readers and patients might be more interested in ‘positive’ or new research findings
*Decision-making authorities in European healthcare systems, such as the Federal Joint Committee in Germany.
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bias, it was striking that none of them assumed responsi-
bility for, or indicated themselves to be in a position to
tackle, this problem. Instead, each group considered it
was ‘somebody else’s problem’.13 14 The whole dissemin-
ation process seems to involve so many different players
on various levels, that it can sometimes be difﬁcult to
identify clearly who is responsible for the (non-)
dissemination of research ﬁndings at each stage of the
process. In table 2, we list stakeholders who should
assume responsibility for the various stages of conduct-
ing a clinical trial and disseminating of clinical trial
documents (Who?). In table 3, the motivations that may
lead the various players to selectively disseminate ﬁnd-
ings, thereby introducing bias in the dissemination
process (Why?), are presented.
DISCUSSION
The phenomenon of (non-)publication and/or non-
dissemination of whole studies based on the nature and
direction of the results has historically been referred to
as ‘publication bias’.3 However, the scientiﬁc evidence-
base can be distorted not only by the absence of a
journal publication of a whole study, but results can also
be reported only partially or in a delayed manner, or be
misrepresented in a way that inﬂuences the take-up and
interpretation of the ﬁndings. Thus, multiple problems,
all related to the dissemination of study ﬁndings, can
come into play.
In our scoping review we found that there is currently
no consistent deﬁnition of ‘publication bias’ and a com-
prehensive framework for its description has not yet
been developed. Multiple published deﬁnitions of ‘pub-
lication bias’ exist. Most of the articles (38/50) in our
data set deﬁned ‘publication bias’ as a form of selective
publication due to various reasons. Thus, despite the
serious consequences of this problem, we found in our
scoping review that there is currently no consistent def-
inition of ‘publication bias’ and a comprehensive frame-
work for its description has not yet been developed.
As a ﬁrst approach to a comprehensive and consistent
framework of (non-) dissemination of research ﬁndings,
we identiﬁed three characteristics ((1) ‘Type of data’,
(2) ‘Format/Product’ and (3) ‘Accessibility’) that need
to be considered when disseminating research ﬁndings
(What?). We then focused on the various players who
could assume responsibility for the various stages of con-
ducting a clinical trial and disseminating of clinical trial
documents (Who?). Furthermore, we tried to describe
the motivations that might lead the various players to
introduce bias in the dissemination process (Why?).
The proposed framework of (non-) dissemination of
research ﬁndings is based on the results from literature
search and expert consensus of the OPEN group. A limi-
tation should be considered when interpreting our
results. We conducted only a very limited literature
search and included only 50 articles, since we were inter-
ested in the most prevalent deﬁnitions of ‘publication
bias’ only. Since we only searched Web of Science, with
the simple search term ‘publication bias’, our literature
search might have favoured older publications and sys-
tematic reviews of primary research, and might have
missed methodological publications. A more compre-
hensive literature search might have concluded in a
wider range of deﬁnitions. Also, the representativeness
of these articles might be limited since all of the
included articles have been published in English, there-
fore language bias might also play a role.
The 2013 version of the Declaration of Helsinki states
that ‘Researchers, authors, sponsors, editors and publish-
ers all have ethical obligations with regard to the publi-
cation and dissemination of the results of research.
Researchers have a duty to make publicly available the
results of their research on human participants and are
accountable for the completeness and accuracy of their
reports’.26 Despite this, many research results never get
disseminated. The (non-)dissemination of study results
is of great importance because it distorts the evidence
for clinical decision-making, which is increasingly based
on syntheses of published research. Using the OPEN
‘What, Who and Why?’ framework, we were able to
clearly structure and comprehensively describe the dis-
semination process and its responsible stakeholders. We
believe that, together with the other results from the
OPEN Project and the recommendations12 derived from
these ﬁndings, our framework will facilitate the develop-
ment of future policies and guidelines regarding
the multifaceted issue of dissemination bias. We hope
that it will help to decrease the problem of (non-)
dissemination of research results and enable clinicians
to base their medical decisions on the most comprehen-
sive evidence available, which should ultimately increase
the quality of patient care.
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